• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Assessing the cancer hypothesis of pulmonary arterial hypertension: the devil is in the detail.

作者信息

Frump Andrea L, Lai Yen-Chun, Lahm Tim

机构信息

Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indiana University School of Medicine, Indianapolis, Indiana.

Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, Indiana.

出版信息

Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1140-L1141. doi: 10.1152/ajplung.00084.2020. Epub 2020 Mar 18.

DOI:10.1152/ajplung.00084.2020
PMID:32186392
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7347276/
Abstract
摘要

相似文献

1
Assessing the cancer hypothesis of pulmonary arterial hypertension: the devil is in the detail.评估肺动脉高压的癌症假说：细节决定成败。
Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1140-L1141. doi: 10.1152/ajplung.00084.2020. Epub 2020 Mar 18.
2
The cancer hypothesis of pulmonary arterial hypertension: the next ten years.肺动脉高压的癌症假说：未来十年
Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1138-L1139. doi: 10.1152/ajplung.00057.2020. Epub 2020 Mar 18.
3
Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension.肺血管阻力在肺动脉高压患者中的临床应用
J Cardiothorac Surg. 2021 Oct 20;16(1):311. doi: 10.1186/s13019-021-01696-4.
4
Adding an important piece to the pulmonary vascular resistance puzzle in pulmonary arterial hypertension.为肺动脉高压中肺血管阻力难题增添了重要一环。
Eur Respir J. 2020 Jul 9;56(1). doi: 10.1183/13993003.00962-2020. Print 2020 Jul.
5
Endothelial CFTR dysfunction and its involvement in the pathogenesis of pulmonary arterial hypertension.内皮细胞囊性纤维化跨膜传导调节因子功能障碍及其在肺动脉高压发病机制中的作用。
Eur Respir J. 2021 Aug 19;58(2). doi: 10.1183/13993003.01645-2021. Print 2021 Aug.
6
The updated cancer paradigm of PAH: recognizing complexity.PAH的更新癌症范式：认识到复杂性。
Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1111-L1114. doi: 10.1152/ajplung.00159.2020. Epub 2020 Apr 22.
7
Multilevel omics: A next step on the way to understanding pulmonary arterial hypertension?多组学：通往理解肺动脉高压之路的下一步？
Thorax. 2019 Apr;74(4):317-318. doi: 10.1136/thoraxjnl-2018-212840. Epub 2019 Jan 24.
8
Deconstructing the Melting Pot in Pulmonary Arterial Hypertension.剖析肺动脉高压中的大熔炉现象
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1329-1331. doi: 10.1164/rccm.202001-0156ED.
9
Checkpoint Kinase 1 Promotes the Development of Pulmonary Arterial Hypertension.关卡激酶1促进肺动脉高压的发展。
Arterioscler Thromb Vasc Biol. 2019 Aug;39(8):1504-1506. doi: 10.1161/ATVBAHA.119.312969. Epub 2019 Jul 24.
10
"Rehab for all!" Is it too early in pulmonary arterial hypertension?“全民康复！”对于肺动脉高压而言，现在提这个是否为时过早？
Eur Respir J. 2019 Nov 7;54(5). doi: 10.1183/13993003.01558-2019. Print 2019 Nov.

引用本文的文献

1
Pulmonary hypertension and the potential of 'drug' repurposing: A case for African medicinal plants.肺动脉高压与药物重新利用的潜力：以非洲药用植物为例
Afr J Thorac Crit Care Med. 2024 Jul 4;30(2):e1352. doi: 10.7196/AJTCCM.2024.v30i2.1352. eCollection 2024.

本文引用的文献

1
The hallmarks of severe pulmonary arterial hypertension: the cancer hypothesis-ten years later.严重肺动脉高压的特征：癌症假说十年后。
Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1115-L1130. doi: 10.1152/ajplung.00476.2019. Epub 2020 Feb 5.
2
Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure.肺动脉高压疾病机制的热点话题：类癌病理生物学、外膜的作用、全身受累及右心室衰竭。
Pulm Circ. 2019 Nov 20;9(4):2045894019889775. doi: 10.1177/2045894019889775. eCollection 2019 Oct-Dec.
3
Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.超越肺部：肺动脉高压的系统性表现。
Am J Respir Crit Care Med. 2020 Jan 15;201(2):148-157. doi: 10.1164/rccm.201903-0656CI.
4
Smooth Muscle Phenotype in Idiopathic Pulmonary Hypertension: Hyper-Proliferative but not Cancerous.特发性肺动脉高压中的平滑肌表型：高增殖但非癌变。
Int J Mol Sci. 2019 Jul 22;20(14):3575. doi: 10.3390/ijms20143575.
5
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.第三个千年之交癌症药物治疗的进展
Front Pharmacol. 2018 Nov 13;9:1300. doi: 10.3389/fphar.2018.01300. eCollection 2018.
6
Proliferative Versus Degenerative Paradigms in Pulmonary Arterial Hypertension: Have We Put the Cart Before the Horse?肺动脉高压中的增殖与退化范式：我们是否本末倒置了？
Circ Res. 2017 Apr 14;120(8):1237-1239. doi: 10.1161/CIRCRESAHA.116.310097.
7
Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.肺动脉高压领域的转化研究进展。从癌症生物学到新的肺动脉高压治疗方法。靶向细胞生长和增殖信号枢纽。
Am J Respir Crit Care Med. 2017 Feb 15;195(4):425-437. doi: 10.1164/rccm.201606-1226PP.
8
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.达沙替尼会引发肺血管毒性并易导致肺动脉高压。
J Clin Invest. 2016 Sep 1;126(9):3207-18. doi: 10.1172/JCI86249. Epub 2016 Aug 2.
9
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.甲磺酸伊马替尼作为肺动脉高压的附加治疗：随机 IMPRES 研究的结果。
Circulation. 2013 Mar 12;127(10):1128-38. doi: 10.1161/CIRCULATIONAHA.112.000765. Epub 2013 Feb 12.
10
Hallmarks of cancer: the next generation.癌症的特征：下一代。
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.